Skip to main content
Home Friends of Cancer Research

Main navigation

  • 25th Anniversary
  • About
    • About Friends
    • Celebrating 25 Years
    • Team
    • Board of Directors
    • Financials & Policies
  • Science & Policy
    • About Breakthrough Therapies
    • Search Breakthrough Therapies
    • Data Driven Insights
    • ctDNA
    • HRD Harmonization Project
    • Cell Therapies
    • Clinical Trial Eligibility Criteria
    • Tumor Mutational Burden (TMB)
    • COVID-19
    • Real-World Evidence
    • Rx Drug Labeling
    • Centers of Excellence
    • Lung-MAP
    • Tolerability in Cancer Clinical Trials
  • News
    • In The News
    • Blog: Engaging Innovation
    • Press Releases
  • Events
    • Upcoming Events
    • Event Archive
    • Annual Meeting
    • Friends-Alexandria Blueprint Forum
  • Patients
    • Prevention, Detection, & Diagnosis
    • Clinical Trials
    • Find a Cancer Center
    • Glossary of Terms
  • Education
  • Publications
  • Donate
 

Post-Market Clinical Trials

The FDA requires some drugs that have already been approved to undergo additional clinical trials in order to confirm safety and effectiveness. These ‘postmarket’ trials are frequently used in cases where Phase 3 trials were too brief to establish safety and effectiveness to the degree of confidence that the FDA ordinarily requires (as with Accelerated Approval drugs). 

More Cancer and Drug Development terms

Home

1800 M Street NW, Suite 1050 South, Washington, DC 20036 - Phone: (202) 944-6700

Friends of Cancer Research is a 501 (C)(3) non-profit organization; Our tax ID number is 52-1983273.

Footer Menu 1

  • About
  • Careers
  • Contact
  • Donate
  • Privacy Policy

Footer Menu 2

  • Policy on Corporate Partnerships
  • Terms & Conditions

© Copyright 2020 Friends of Cancer Research. All rights reserved.

Social menu footer

  • Linkedin
  • Twitter
  • Youtube